Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good afternoon and welcome to Revenio, a group earnings call for Q1. My name is Jouni Toijala and I'm the group CEO. And with me here, as normally we have as well our CFO, Robin Pulkkinen. Uh, agenda for today. So I'll start with the highlights for the Q1. Uh, then Robin is going to go through the, uh, financials, shareholder, uh, structure. Uh, plus reiterate, uh, the uh, guidance. Uh, so let's move on to the Q1. So the Q1, uh, started slightly softly, as expected. Uh, however, the cash flow was, uh, strong. So net sales ended up to 23.6 million, reported growth, 1.8%. If we look the currency adjusted number. So that was slightly down, uh, 0.5% EBIT, uh, down from 6.2 to 5.1. Uh, the biggest contributor for that one was the FDA approval related costs. And Robin is going to do a bit more, deeper dive, uh, to the, uh, cost side in his part of the presentation. Cash flow was strong. So, uh, 4.6 million for the Q1. And the big contributor for the good cash flow, uh, was related to the, uh, non-payment, uh, for the long term incentive scheme, plus also really, really minor payments for the short term incentive, uh, schemes. So if going to the business highlights for the for the Q1. So uh, sales in the US and Europe, Middle East and Africa, uh, was strong. Uh, a couple of highlights from the product side, iCare IC200 tonometer. Uh, continued to sell really well like, uh, during the Q4. Uh, also the iCare DRSplus sales was, was really good. Uh, during the Q1 then, as mentioned earlier, uh, so we we we have started to work, uh, with the FDA approval related to the iCare DRSplus. iCare ILLUME screening solution plus the AI, and that cost, uh, occurred, uh, partly during the Q1 this year. So roughly €600,000. Uh, then, uh, if going back to the Q2, Q3, uh, last year. So we had, uh, lots of headwind from the private equity owned optometry sector in the USA. So on the positive note, we saw, uh, some uh, uh, increased activity now during the Q1, uh, from the private equity driven optometry. So that's a clear clearly positive side. Uh, on the product side. iCare's MAIA microperimeter is progressing according to the plan. So based on the current plan, we have the intention to launch the product towards the end of Q4 this year and then, as in all quarters. Lots of activities, of course, related to sustainability themes and especially now during Q1, lots of activities around the double materiality assessment. So that's working according to the plan as well. But over to you, Robin.
Thank you, Jouni.
So like Jouni mentioned, Q1 sales were slightly soft, of course, just looking at the numbers, you may say it's, well, that's what we think when we say that soft. But then we did have tough comparables. And the good news is also that it did go pretty much like we planned. So we were not internally surprised. It has no impact on our longer-term guidance. So we knew Q1 was going to be challenging. Q2 and Q3 are the quarters where we are having easier comparables and then of course, Q4 again, we have challenging comparables. So, I think the Q1 and Q4 were also internally expected to be a bit softer, year over year, gross margin. We were able to protect. Well, so the, the, not big change there. So 70.3%, and like Jouni mentioned, the profitability is down, driven by the FDA approval related costs. We did highlight that at the end of last year or the Q4, that we do have some cost headwinds this year. So the FDA trials for the new products were expected to be roughly 1.5 to 2 million euros this year. And then, of course, the salary side, where we did pay record low incentives this spring. But those records were accrued last year. So in the costs in the books for last year. But the cash flow impact this year, earnings per share, 13.7 cents. And the net gearing, minus seven versus -13 last year. So here you can see a bit more of the sales trend. The Q1 again slightly below the trend line, but that's been the case for every Q1. Also earlier. So the 1.8% reported growth, slight decline on the FX adjusted and especially the EMEA and the US sales were performing really well. And then the profitability side, so that we can see here that it did come down. But we did kind of anticipate this to happen also. So, the FDA costs, I think, seem to be a bit higher than maybe the market was expecting for the first quarter. Uh, the analyst reports, I think, were on average expecting lower costs for Q1. Um, we haven't really specified in which quarter these costs are coming this year. And, uh, I think it's fair to expect that there will be quite a bit of quarterly fluctuation in how those costs come in. And of course, the bonuses. We're looking at the profitability for this year. So like I mentioned, the bonus accruals last year were pretty small. Quite small. So looking at this year, expecting to remain within the guidance, the payroll costs will be higher this year compared to last year. Cash flow reached a record high. I think we haven't been even close to this level in the earlier years, for many years going back. Traditionally, the STI and LTI incentive programs are paid out in the first quarter. And now that those payments were smaller, that is the main reason for the increase in operating cash flow. Of course, we also paid less in taxes than in the comparable period. And then the trade receivables came down, which we also at the end of Q4 discussed that the AR was quite high, due to a really strong end of the year. So the AR coming down was also pretty much what we had planned and foreseen earlier. The balance sheet remains strong. So the equity ratio is almost 75%. It's actually up more than 10% year over year. One big reason there is that last year, I think the dividend was paid in Q2, like this year, but the AGM was in March. So the equity postings for the dividends were already in the balance sheet. So that was one reason, so in Q2 this year, we'll also have the dividend payment in the equity. So the equity ratio probably will come down slightly. So, $0.38 of dividends paid based on the AGM decision on April 4th. And those payments went out around mid-April this year. Shareholders. A couple changes here. Um, the forums seem to have noticed also that William Demant Invest has increased their ownership, so went from slightly below 18% at the end of the year to 18.73% now at the end of Q1 and then also we have a new, not new shareholder, but Berenberg Funds. They have been our shareholders for a long time back, but have now increased their ownership, and become the sixth largest shareholder. On the top ten list. So other than that, all the others are in the same order and pretty much at the same level as they were at the end of the year. Foreign ownership is now slightly above 50% again, after being just under 50% at the end of the year, the country split. Hasn't much changed. So nothing really to highlight there. Uh, the guidance remains the same. Revenue growth, exchange rate adjusted net sales are estimated to grow 5 to 10% from the previous year, and profitability, excluding non-recurring items, is estimated to remain at a good level. No change. Uh, here. Good. And I think we're good for questions.
Yes. Thank you, Robin. And it's time for questions, please.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Nicole Kangas from CB. Please go ahead.
And this is from SEB. Thank you for the presentation. I have a couple of questions. Uh, starting with that, you said that you have seen some improvement in activity between segments. So how much was this already visible in Q1 numbers and what kind of level it currently is compared to the level prior to the challenges in the segment.
So some order activity and then an increase in the pipeline related to the RFQ. So um, I think that's the current status quo. And thank you for the questions.
Yeah. Great. Uh, okay. Uh, then. Has anything changed? How do you view the market trend developing compared to the Q4 conference call? Two months ago. So, do you still see some light in the trend?
I would say that if not, I so not too much change. So, I think it's the private equity-driven optometry that's more positive than if you go back to Q2, we go back to Q3. So I think that there's a bit more footfall on the optometry side. I think what we were expecting from the interest rate perspective, Q3 and Q4 last year, perhaps we were expecting, uh, interest rates to come down slightly faster than what is now planned. But uh, in summary. Private equity-driven optometry. Uh, now more activity. So that's not totally standstill. I think that's a good sign and perhaps a bit more foot traffic to the optometry as well.
Okay. Okay. Thanks. Then, still one question related to your costs, even though you already elaborated a bit on the costs, but in general, the fixed cost side, I understand the reason for the increase, but that's. And what kind of level do you expect the fixed costs to be at for the rest of the 2024 competition?
I think the biggest variable items are related to the clinical trials we have ongoing and are starting this year. In general, as long as we expect to remain and do remain within the guidance, then the bonus accruals are going to be higher than last year. So, the payroll costs are going up. We hired, I think, the average headcount went up by seven people last year. So from 212 to 219. So, the total payroll package is also slightly increasing but not by much. Of course, then the salary inflation has been around 4 or 5%. So, those kinds of things together are probably the variable parts there. But I'd say the biggest bit still open. Still, how the costs are coming for each quarter is related to the clinical trials. Which is something we keep on working on, but we don't have a full schedule for every quarter or how it's going to impact yet.
Okay. And do you expect also salary inflation of 4 to 5% also for this year?
Or sorry, the line was a little bit bad. I didn't catch the question.
So you said that the salary inflation has been at the 5% level. So do we expect that for this year, or were you talking about last year?
So I tend.
To think.
That was for this year. The salary inflation is roughly there. Yeah.
All right. Great. That's awesome.
The next question comes from Daniel from Danske Bank. Please go ahead.
Hi, Daniel from Danske Bank.
I have also a few questions here. Maybe on the cost side, on the R&D cost headwinds that I guess you highlighted already in the Q4 report. I do remember that the target range was about 1.5 to 2 million extra for this year. So, are you still within this previously talked about range? Now, after Q1? Yes.
That hasn't changed. So, it's still the same range. I think, at least it seems like the market expected it to be more end heavy. However, we did incur significant costs already in Q1. But there's a good chance that there are going to be big quarterly fluctuations there. So it's, uh, it's hard to say exactly how it's going to play out.
All right. That's very clear. And, uh, maybe, maybe just continuing that, uh, this MAIA related R&D costs. Are these included in this paper? Uh, as well?
Yeah.
Okay. Then, the second topic on the HOME2 reimbursement, I guess that, as well, in Q4, you talked about H1 2025 when you would be expecting the decision on that. So I guess you are seeing news of this maybe a bit faster than previously anticipated. So, has anything changed for the better, or was it just faster in terms of your submission date and so on?
Let's discuss milestones on this one, which we are following carefully. So first, one is Q4, when we should get the information related to the application for the codes. And, the first key step is to get the codes. So, the reimbursement codes, and that's a timeline for Q4 this year. And then of course, after that comes the payer insurance company side alignment in order to be able to get the reimbursement. So, then we have that one for Q2 2025. So, I think those are the two things that everybody should be following up on, that those are going according to the plan.
All right. Thanks. Thanks for that clarification, I guess. Also, that's the topic. I think it's still open. Whether you will be taking or whether you will be getting full or partial coverage. I mean, do you have any sort of scenarios on this one, and what's your view on this topic.
So we are looking at the codes for the hardware. So currently, there are existing remote monitoring training related codes. But now we are looking at the reimbursement codes for the hardware side. And then of course, we are looking as high as we can. But that's not fully under our control. What's going to be the result? But really, the date or the time? The time period is Q4. So we have to come back to this one. Q4.
Alright, that's clear. The final question is on the iCare HOME2 tonometer FDA approval. And the timeline on that one. Are you sticking with the timeline of H1 2024 as well, or has there been any development on that?
There's been movement on that one. So we did the press update. Then we got, just a couple of days back, So we got the information related to the clinical trial requirement. So, what's the scope of the clinical trials? We are analyzing the data as we speak, and there seems to be a wish from the FDA that the clinical trial scope perhaps should be extended. So we are discussing with the FDA. So I think that it is going to have an impact on the timeline. And I would say that most probably not the first half of next year. So that's my current understanding. I would, perhaps to be sure, push it to the second half of next year. And of course, it's an FDA approval process. So they tend to have a tendency to take time. But that's the latest. And we just got the info from the FDA a couple of days ago. So we are analyzing that one and being in contact with the FDA on that. But that's the latest, really, I mean, really, in a couple of days.
Okay. And this scope extension, it won't have any impact on the R&D cost side, at least this year.
Or this year, you know. No. So we were allocating from 1.2 to 1.5 million for aluminum, then the remaining part for the MAIA, as Robin explained. So no change on the cost side for this year for sure.
Okay. That's all for me. Thanks for the answers.
Thank you, Danielle.
The next question comes from Gianni Sandoval from Nordica. Please go ahead.
Thanks for the good presentation from Nora. You had some larger multi-year orders in Q4 too. If I remember correctly, Germany and also some US deliveries scheduled for this year. So can you give any comment on the deliveries of this and the timeline?
We did first deliveries for both countries. Imaging devices, tonometers already in Q4. So during Q1, we also continued to deliver DRS pluses to the clients. So that's going according to the rollout plan.
Okay. Perfect. Then maybe a follow-up on the pipeline situation. You said that by the end of Q4 and I think we went through the HOME2 and FDA approval situation, but is there some other new product launches now scheduled for 2024?
That's an interesting question. I would love to give an answer to that one. So I think this is perhaps a bit different statement, but we have been working quite a lot on the R&D side related to the coming year. So I think the time will show, in the coming quarters, if there's something new to come. Sorry for the unclear answer.
That's okay, that's okay. Hey, then maybe lastly, on the guidance, you are intact with the guidance. And, after a bit of a soft Q1 as you said, how is your visibility now going forward, how long visibility do you have and how confident are you with your guidance?
Yeah, I think Q1 went very much like we thought it was going to go. So the way that we thought it was going to go when we gave the guidance. So nothing's really changed there. The Q2, Q3 are, from the comparable points, hopefully the easier quarters. But of course, the visibility for us hasn't really changed. So we delivered a ton of tonometers. Our backlog is maximum two weeks. And then for imaging, it's not more than four weeks, even in rare cases. So, our visibility, what we've sold for Q2 is probably a couple of 20, 20, 30% so far. So we don't even know yet what Q2 is going to be like. So, the visibility is quite short. Uh, and um.
And that's normal.
Normal. Yeah. For us. Yeah.
Yes. Okay. Well, let's proceed.
Up on that. Can you, can you give any, any, you know, sequential color maybe, maybe on the, on the sales trend now towards the end of Q1.
Uh.
Looking at April, we are executing according to the plan, I think that's Robin. Fair to say. So, if we look at the current numbers we have. So we are executing according to the plan, which is of course good.
Okay. Perfect. That's all for me.
Thank you, Jouni.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. The next question comes from Pierre Rosvall from Carnegie Investment Bank. Please go ahead.
Ione. Hi, Robin. Thank you for the presentation. I'm going back to the demand situation in Q1, and you said, or you reported sales growth of slightly shy of 2%. Uh, but can you give some more color on the different products in addition to iCare DRSplus, which you said grew strongly? And I think you also said iCare IC200 tonometer. Growth, growth. Well, so what happened in the other product categories?
Yes, those two were. Uh, thanks. Hi. So, those two were the highlights. We saw really strong growth in the iCare IC200 tonometer, especially. The same for the iCare DRSplus. And then, of course, the add-on family, according to the normal, steady growth trend, and the same applies also for the other products. But those were two highlights where we actually performed slightly better than expected. So that was the logic. Why we highlighted them. Anything, Robin? Any flavor you would like to add? Yes.
I think, like I said, the iCare IC200. It's important to understand it's partly cannibalizing the iCare IC100 sales, so it's not only new add-on sales. So, in the US, it seems like the sales are transferring more towards the highest-end device, which is the iCare IC200. Which has then resulted in a decline, partly, of the iCare IC100 sales.
Okay, thanks. I'm just trying to understand if there are any product categories that declined, since the reported sales or the FX-adjusted sales were actually down slightly. So, if the iCare IC200 sales are growing very strongly, what kind of products are then maybe declining?
Well, often it's difficult as one quarter is a short review period. So, there are big, especially in the imaging devices. There are big differences between months and quarters. So, definitely, the biggest growth comes from there. And then, I think for the tonometers, it's pretty small. Still, for us. So, some products have gone up, some have gone slightly down. But overall, I think the comparable quarter was so challenging or tough that the sales were quite okay from our view when it comes to Q1, but I wouldn't necessarily disclose exactly what happened to each product group, but some went up, some went down.
Alright. That's clear. Thank you. Then, do you have any comments on the iCare HOME2 tonometer? How is that performing? Any numbers to share?
Steadily growing like in earlier quarters. So, not the step-change growth but steadily growing as before. And of course, the key to this step-change growth is the reimbursement. But that's the one we covered already. Any other flavor, Robin, on that?
Yes, remember the screening. If you want to say a few words, what do you think about the new screening accounts? We have been.
Ah yes. So, on a positive note, when it comes to the iCare ILLUME and the iCare DRSplus. So, we have been gaining quite a lot of traction, especially in Europe. So, we have tens of clients in live use for screening here in Europe. So that's of course good, good progress on the, on the ESG side.
Uh, that sounds good. And, uh, when will the needle move in terms of revenues for that?
It's 12-month subscriptions that they sign up for. So, it's not very fast to get it to hockey stick, but at least there's good traction. Uh, a lot of requests, even for larger programs in different countries, uh, for, for screening the population. So, uh, looks quite good from our end.
And of course, for this year, we have budgeted in the hardware sales for the screening. So, coming back to the business, it's a combination of the additional hardware sales to the new segments, plus the report-based invoicing for the AI-based reports, plus, of course, the iCare ILLUME screening solution. So.
Right? Uh, good. Uh. Thank you. Then, if I may still continue. Regarding the plans for the clinical study, you mentioned that you have got some indications to broaden the scope, but what kind of scope are we talking about? Can you share any color on the number of patients, how many locations, etc.? And just to make it clear, so when you talk about the second half of 2024, that's when you plan to be able to submit the application. Have I understood correctly?
Thank you, that's good. Thank you for asking the question and clarifying the situation. So, we have already completed the so-called pre-submission earlier. And then after we did the pre-sub. So then there's roughly 99, 90 days, three months for the FDA to come back. So they came back last week on Friday. And now we are looking for their feedback. Uh, what kind of sites to include. What kind of patient population to include. So that's still in progress. And then after we have now done the study, made the revisions, then we do a new phase, then we start the clinical trials. And when I was referring to the second half of next year. So I'm really hoping that we are able to submit the application well before that. So that was the logic. But now we are crunching and analyzing the feedback from the FDA. So we have to run the power calculation and certain things again based on the FDA feedback. So not able to answer yet in detail to your question.
All right. So just to clarify, you expect to receive market approval during the second half of next year.
If everything were to go in an extremely nice and smooth way, that would be nice. But then I think all of us, when dealing with the FDA and these more complex clinical studies, of course, there are risks that it might not happen, but that's the direction we are currently working towards.
Good. That's clear. Thank you. Uh, then let me check my questions. Um. Uh, yeah. Finally. Maybe still a comment on the contingent consideration of roughly €8 million. You have referred to in your report. So do you have any more additional color on the likelihood of this occurring and what kind of technology or what kind of company investment are we talking about?
Uh.
Currently, I would say that if everything goes according to the plan, and that's all because of the NDAs and confidentiality that we are able to say so. So currently everything is going according to plan. And then we'll come back to this one during Q3.
All right. Um, okay. Uh, I think that's all for me. Thank you so much.
Thank you, Peter.
Thank you.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. The next question comes from Charles Weston from RBC. Please go ahead.
Hello. Thanks for taking my question. I'm standing in for Jack Reynolds. Clarification, just one, please. Could you comment on what you think the trajectory of the iCare HOME2 tonometer might be once you do get the reimbursement? And it is kind of, you know, on the schedule for the insurance companies. What will be required after that to get to the hockey stick growth that you mentioned? And how fast might that be? What timeframe are we thinking?
So, hopefully, everything goes smoothly and we get the codes and the reimbursement. Also agreed with the insurance companies early next year. There is quite a bit of sales already today where in Europe, more than half of our unit sales are paid by the patients out of their own pocket. So, there is clear evidence and common understanding among colleagues that measuring the eye pressure at home is the best way to manage glaucoma. And, for an insurance company, if a person goes blind, it's a seven-figure sum of money that it costs for them to pay to the patient that goes blind. So, it seems to be that the insurance companies fully understand also that paying 2500 to 3000 for reimbursement for a device that helps to protect the sight of the patients. Hasn't been a very big obstacle to convince them. So, in a way, if the device is free for the patients, of course, we do think that there's a very good chance for very strong growth in those sales. But the market, what we expected and kind of in the CMD disclosed that our understanding of the whole market is roughly 750 million annually, by 2030. And there is no other device available than our device. So, of course, hard to exactly say. I think your guess would be almost as good as my guess what it could be. It's still early and difficult to forecast.
I'm sure your guess would be better. Is it perhaps in terms of the marketing effort that you'll put behind it once you do get that? If you do get that and it's an attractive number. You know, would that trigger a material investment from you in terms of marketing and getting that message out? But it's now available, in inverted commas, for free for the patients.
And the current distribution model is following that. We have distributors in the USA and their growth is really good. So, they are going to cover part of the burden in terms of the marketing, of course, if we get the codes, if we get payers aligned. So, according to the normal process, we are then going to evaluate how much more money we are going to put behind the iCare HOME2 marketing. But I think we would perhaps target the marketing more towards the eye care professionals because they have to prescribe the device and then it, of course, would require lots of money to start the business-to-consumer side of the marketing. So, I would say that the marketing spend increased, but not an endless amount of money because we are not planning to direct marketing straight to consumers. Rather, the eye care professionals and also the distributors are covering part of the marketing spend.
Just good. Thanks very much.
Hey. Thanks, Charles.
There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Thank you for the participation and next time, early August. Related to the Q2 earnings call, and let's hope that spring is coming here in Finland. Doesn't look like it yet, but have a good spring and have a good summer all. And next time let's talk, early August. Thank you. Bye bye.
Bye. Thank you.



















